Drug Profile
Tiragolumab - Genentech
Alternative Names: anti-TIGIT - Roche; MTIG-7192A; RG-6058; RG6058-10; RG6058-11; RO 7092284Latest Information Update: 27 Jun 2026
Price :
$50
*
At a glance
- Originator Genentech
- Developer Chugai Pharmaceutical; Genentech; National Cancer Institute (USA); Roche; Washington University School of Medicine
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Squamous cell cancer
- Discontinued B-cell lymphoma; Cervical cancer; Gastric cancer; Liver cancer; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Rectal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer
Most Recent Events
- 10 Jun 2026 Hoffmann-La Roche terminates a phase III trial in Non-small cell lung cancer (Second-line therapy or greater, Late-stage disease, Combination therapy) Argentina, Australia, Brazil, China, Italy, Japan, Poland, South Korea, Taiwan, Thailand and Turkey (IV) (NCT06267001)
- 15 Apr 2026 Roche terminates a phase Ib/II Morpheus C trial for Gastric cancer or Gastroesophageal cancer (Combination therapy, Late-stage disease, Metastatic disease, First-line therapy) in China (IV, Infusion) as the sponsor decided not to continue development of certain treatment combinations (NCT05251948)
- 02 Feb 2026 Roche terminates a phase II trial in Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Neoadjuvant therapy) in USA, Switzerland, Australia, Italy, Netherlands, Poland, South Korea, Spain (IV) as data became available from phase III trials (NCT04832854)